The use of reimbursement data for timely monitoring of vaccination coverage: the example of human papillomavirus vaccine following public concerns about vaccine safety

Table 1 HPV vaccination coverage (%) and its 95 % confidence interval at 15^th, 16^th and 17^th birthday as of June 30 2014, France

Half year of birthday	2010	2010	2011	2011	2012	2012	2013	2013	2014
Half year of birthday	s1	s2	s1	s2	s1	s2	s1	s2	s1
n	877	914	1316	1340	1431	1430	1323	1408	1404
1 dose at 15	23.7 [20.9–26.5]	24.7 [21.9–27.5]	26.5 [24.1–28.9]	25.6 [23.3–27.9]	19.8 [17.1–21.9]	17.5 [15.5–19.5]	16.3 [14.3–18.3]	17.5 [15.5–19.5]	17.7 [15.7–19.7]
3 doses at 16	–	–	26.5 [23.6–29.4]	27.4 [24.5–30.3]	28.2 [25.8–30.6]	24.2 [21.9–26.5]	22.0 [19.9–24.1]	20.1 [18.0–22.2]	18.6 [16.5–20.7]
3 doses at 17	–	–	–	–	31.2 [28.8–33.6]	30.3 [27.9–32.7]	32.0 [29.5–34.5]	27.2 [24.9–29.5]	26.3 [24.0–28.6]

ISSN: 1471-2458